Penumbra, Inc. (NYSE:PEN) Director Harpreet Grewal Sells 875 Shares
Penumbra, Inc. (NYSE:PEN – Get Rating) Director Harpreet Grewal sold 875 shares of the stock in a transaction that occurred on Wednesday, March 15th. The stock was sold at an average price of $254.98, for a total transaction of $223,107.50. Following the transaction, the director now owns 10,535 shares in the company, valued at approximately $2,686,214.30. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
→ Urgent Warning (From Weiss Ratings)
Harpreet Grewal also recently made the following trade(s):
- On Wednesday, March 1st, Harpreet Grewal sold 710 shares of Penumbra stock. The stock was sold at an average price of $259.48, for a total transaction of $184,230.80.
Penumbra Trading Down 1.9 %
Penumbra stock traded down $4.96 during trading hours on Friday, reaching $263.00. 389,905 shares of the company’s stock were exchanged, compared to its average volume of 335,047. The company has a quick ratio of 2.91, a current ratio of 5.21 and a debt-to-equity ratio of 0.02. The firm’s 50 day simple moving average is $253.72 and its 200 day simple moving average is $215.22. Penumbra, Inc. has a twelve month low of $114.86 and a twelve month high of $274.71. The firm has a market capitalization of $10.04 billion, a PE ratio of -4,383.33 and a beta of 0.52.
Penumbra (NYSE:PEN – Get Rating) last issued its quarterly earnings results on Thursday, February 23rd. The company reported $0.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02. The firm had revenue of $221.22 million during the quarter, compared to the consensus estimate of $217.03 million. Penumbra had a positive return on equity of 0.66% and a negative net margin of 0.24%. The business’s revenue was up 8.4% compared to the same quarter last year. During the same period last year, the business posted $0.10 EPS. Research analysts predict that Penumbra, Inc. will post 1.29 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on PEN shares. Needham & Company LLC upped their price target on shares of Penumbra from $235.00 to $300.00 and gave the stock a “buy” rating in a report on Friday, February 24th. StockNews.com assumed coverage on shares of Penumbra in a report on Thursday. They set a “hold” rating for the company. Piper Sandler assumed coverage on shares of Penumbra in a research note on Monday, January 30th. They issued an “overweight” rating and a $275.00 price objective for the company. TheStreet raised shares of Penumbra from a “d+” rating to a “c-” rating in a research note on Friday, January 13th. Finally, Citigroup increased their price target on Penumbra from $270.00 to $303.00 and gave the company a “buy” rating in a research note on Monday, February 27th. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $265.42.
Institutional Trading of Penumbra
Several large investors have recently made changes to their positions in PEN. Raymond James & Associates grew its stake in shares of Penumbra by 8.1% in the 1st quarter. Raymond James & Associates now owns 8,565 shares of the company’s stock valued at $1,903,000 after buying an additional 641 shares during the period. Citigroup Inc. boosted its stake in Penumbra by 44.5% during the 1st quarter. Citigroup Inc. now owns 4,979 shares of the company’s stock valued at $1,106,000 after purchasing an additional 1,534 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in Penumbra by 15.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,211 shares of the company’s stock valued at $269,000 after purchasing an additional 164 shares during the last quarter. Great West Life Assurance Co. Can boosted its stake in Penumbra by 8.0% during the 1st quarter. Great West Life Assurance Co. Can now owns 19,045 shares of the company’s stock valued at $4,348,000 after purchasing an additional 1,417 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Penumbra by 3.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 90,610 shares of the company’s stock valued at $20,123,000 after purchasing an additional 2,717 shares during the last quarter. 82.42% of the stock is currently owned by institutional investors and hedge funds.
Penumbra Company Profile
Penumbra, Inc engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. Its target markets include interventional neuroradiologists, neurosurgeons, neurologists, cardiologists, radiologists, and vascular surgeons.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Penumbra, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Penumbra wasn’t on the list.
While Penumbra currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
